Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Dynepo Appellate Decision Gives TKT Another Chance Against Amgen Patents

  • News

Executive Summary

Transkaryotic Therapies will have a second chance to argue that its gene activated-EPO product Dynepo does not violate patents for Amgen's erythropoietin product Epogen following a Jan. 6 decision by the D.C. federal appellate court

You may also be interested in...



TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model

Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions

TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model

Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions

Wellbutrin SR Patent Case Will Be Early Application Of Festo Ruling

GlaxoSmithKline's defense of its Wellbutrin SR (bupropion sustained release) patents will be an early real world application of the Supreme Court's decision in the Festo case

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By